BioMarin Pharmaceutical Hits $1 Billion Revenue Milestone, Advances Rare-Disease Pipeline

Résumé détaillé

BioMarin Pharmaceutical (NASDAQ:BMRN) is advancing a group of newly acquired rare-disease drug candidates while integrating Amicus Therapeutics and working to reduce debt, executives said during a company discussion. Chief Financial Officer Brian Mueller said third-quarter revenue rose 32% to $1 bi